<DOC>
	<DOCNO>NCT01475578</DOCNO>
	<brief_summary>The objective phase II study STA-1 capsule make preliminary evaluation clinical efficacy safety STA-1 capsule order base dosage study structure plan project , dosage study structure phase III study confirm .</brief_summary>
	<brief_title>Study STA-1 Capsule Patients With Vascular Dementia ( Marrow-Sea Deficiency )</brief_title>
	<detailed_description>This phase II clinical trial plan double-blind , double-dummy , active-controlled , parallel , comparative , multicenter design . Two hundred 40 eligible subject plan recruit 5 study center . The treatment period plan protocol 3 month 5 study visit include Randomization visit ( Day 0 ) , three post-treatment visit ( 1 2 month Randomization visit Final visit ) 1 follow-up visit make 6 month Randomization visit . After subject recruit study read sing ICF , arrange collect information demographic , medical history , allergy history , medication history , concomitant medication . Laboratory physical examination include vital sign perform , Hachinski Ischemia Score ( HIS ) , Mini-Mental Status Examination ( MMSE ) , Classification Marrow-Sea deficiency evaluate ensure subject 's eligibility enter study . After subject confirm eligible , randomly assign either STA-1 Ergoloid Mesylates group . Blessed-Roth Behavior Scale ( BBS ) Activities Daily Living ( ADL ) Scale measure subject randomize . These subject dispense study medication 1-month use . The eligible subject request bring back unused study medication , , study center 1 , 2 , 3 month ( Final visit ) Randomization visit . At visit , measurement MMSE , BBS , ADL scale , Classification Marrow-Sea deficiency collect . Information concomitant medication AEs also record . Physical laboratory examination perform Final visit . Each subject dispense study medication his/her subsequent treatment period month-1 -2 visit . Unused study medication collect drug accountability document . Subjects dismiss study Final visit . Subjects measure MMSE , BBS , ADL scale 6 month Randomization visit available follow-up evaluation .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Ergoloid Mesylates</mesh_term>
	<mesh_term>Dihydroergotoxine</mesh_term>
	<criteria>1 . Meeting criterion dementia accord Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) 2 . Meeting criterion vascular dementia accord National Institute Neurological Disorders StrokeAssociation Internationale pour la Recherche et l'Enseignement en Neurosciences ( NINDS/AIREN ) 3 . With MiniMental State Examination ( MMSE score ) ≦17 ( illiteracy ) ; ≦20 ( elementary school ) ; ≦24 ( high school ) 4 . With Hachinski 's ischemic score ( HIS ) ≧7 5 . With marrowsea deficiency Chinese medicine 's perspective 6 . Classified mild moderate dementia base MMSE score 7 . With body weight 45 95 Kg 8 . Aged 45 80 year old ( inclusive ) . Either gender eligible . Female subject must postmenopausal ( least 1 year ) woman without fertility 9 . Having sign informed consent form 10 . Correct understanding pharmaceutical research good compliance study personnel 's observation evaluation 1 . Dementia besides study indication base DSMIV NINDS/AIREN , e.g . Alzheimer 's disease , Lwey body disease , etc . 2 . With HIS &lt; 7 3 . Diagnosed significant depression base DSMIV score &gt; 8 mental diseases/disorders 4 . With cognitive dysfunction cause head impairment 5 . With medical history epilepsy , encephalitis , disease may result dementia , e.g . Parkinson 's disease , Huntington disease , Pick disease , etc . Patients epilepsy attack occasionally examine first visit electroencephalography ( EEG ) exclude study test result positive . 6 . With certain disease may interfere evaluation cognitive function , include abuse alcohol , DSMIV diagnose abuse drug mental drug past 5 year . Severe anemia patient also exclude . 7 . With severe mental dysfunction , e.g . hemiplegia , aphasia , visually hear impairment , etc . 8 . With cardiac disorder , e.g . heart rate ≦ 50 ≧ 180 times/minute 9 . With supine sit Systolic blood pressure ≦ 100 ≧ 180 mmHg 10 . With disease , especially hepatic , renal , cardiac disorder , e.g . ALT/SGPT AST/SGOT &gt; 3 time upper limit normal range , serum creatinine &gt; 177 umol/L ( 2mg/dL ) , congestive heart failure ( cardiac function 24 classification ) 11 . With malignant neoplasm 12 . With thyroid dysfunction syphilis 13 . Failed control diabetes . Diabetes patient enter study unless status become stable dietary modification , take hypoglycemic agent , receive insulin . 14 . With asthma chronic obstructive pulmonary disease 15 . With multiple neuritis 16 . With myasthenia gravis amyotrophic 17 . With severe indigestion , gastrointestinal obstruction , gastric duodenal ulcer , gastrointestinal disease affect drug absorption 18 . With glaucoma 19 . Ever attend clinical trial past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Vascular Dementia</keyword>
</DOC>